Drug Profile


Alternative Names: BILN 2061 ZW; BILN-2061

Latest Information Update: 11 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim (Canada); Boehringer Ingelheim Pharma KG
  • Developer Boehringer Ingelheim Pharma KG
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 11 Dec 2008 Discontinued - Phase-II for Hepatitis C in Canada (PO)
  • 11 Dec 2008 Discontinued - Phase-II for Hepatitis C in Germany (PO)
  • 01 Jun 2004 Suspended - Phase-II for Hepatitis C in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top